Study Evaluating the Contribution of MRI for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Patients With Infiltrative Breast Cancer
- Evaluate the feasibility (reproducibility and repeatability) of MRI for assessing tumor
vascularity in women receiving neoadjuvant chemotherapy for infiltrative breast cancer.
- Compare the results obtained by semiquantitative measurement of vascularization (MRI)
vs traditional empirical evaluation.
- Evaluate the MRI accuracy for the measurement of tumoral volume after completion of
OUTLINE: This is an uncontrolled, nonrandomized study.
Patients receive neoadjuvant chemotherapy comprising epirubicin hydrochloride IV and
docetaxel IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of
disease progression or unacceptable toxicity.
Patients undergo dynamic-contrast MRI before treatment, 3 weeks after the first course of
chemotherapy, and 3 weeks after the completion of chemotherapy. They also undergo a
bilateral mammogram and sonography and clinical examination.
Within 22-35 days after completion of chemotherapy, patients undergo breast-conserving
surgical resection of tumor and lymph nodes or mastectomy.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Allocation: Non-Randomized, Primary Purpose: Diagnostic
Reproducibility and repeatability of MRI
Fabienne Valentin, MD
United States: Federal Government